Disc Medicine to Participate in SVB Securities Global Biopharma Conference
WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat in a virtual format at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 8:40 a.m. ET.
A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available.
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Verge Scientific Communications
Investor Relations Contact
Stern Investor Relations